Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.

Autor: Dimopoulos, Meletios A.1 (AUTHOR) mdimop@med.uoa.gr, Migkou, Magdalini1 (AUTHOR), Bhutani, Manisha2 (AUTHOR), Ailawadhi, Sikander3 (AUTHOR), Kalff, Anna4 (AUTHOR), Walcott, Farzana L.5 (AUTHOR), Pore, Nabendu5 (AUTHOR), Brown, Miranda5 (AUTHOR), Wang, Fujun5 (AUTHOR), Cheng, Lily I.6 (AUTHOR), Kagiampakis, Ioannis7 (AUTHOR), Williams, Marna8 (AUTHOR), Kinneer, Krista8 (AUTHOR), Wu, Yuling6 (AUTHOR), Jiang, Yu6 (AUTHOR), Kubiak, Robert J.6 (AUTHOR), Zonder, Jeffrey A.9 (AUTHOR), Larsen, Jeremy10 (AUTHOR), Sirdesai, Shreerang4 (AUTHOR), Yee, Andrew J.11 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Dec2024, Vol. 65 Issue 12, p1789-1800. 12p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje